Drug Profile
Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb
Alternative Names: CXL-1036; HNO donors - Bristol-Myers Squibb; HNO prodrugs - Bristol-Myers Squibb; nitroxyl donors - Bristol-Myers SquibbLatest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Cardioxyl Pharmaceuticals
- Developer Bristol-Myers Squibb
- Class Nitrogen oxides; Small molecules
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic heart failure; Pulmonary arterial hypertension
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Chronic-heart-failure in USA (PO, Capsule)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (IV)